Ecolab (ECL)
(Delayed Data from NYSE)
$253.55 USD
-1.78 (-0.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$253.55 USD
-1.78 (-0.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Zacks News
Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.
GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS
by Zacks Equity Research
GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
by Zacks Equity Research
GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.
Here's Why Ecolab (ECL) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised
by Zacks Equity Research
Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.
Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.
Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.
Here's Why Ecolab (ECL) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.
Ecolab (ECL) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Ecolab (ECL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ecolab (ECL) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ecolab (ECL) delivered earnings and revenue surprises of 0.75% and 0.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.
U.S. Silica (SLCA) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
U. S. Silica's (SLCA) earnings and sales miss estimates in the first quarter amid lower sales volumes in Oil & Gas.
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
by Zacks Equity Research
Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.
Is Ecolab (ECL) Stock Outpacing Its Basic Materials Peers This Year?
by Zacks Equity Research
Here is how Ecolab (ECL) and Pan American Silver (PAAS) have performed compared to their sector so far this year.
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.